Leslie M Shaw

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Acta Neuropathol 121:597-609. 2011
  2. ncbi Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
  3. ncbi Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
    John Q Trojanowski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 6:230-8. 2010
  4. ncbi CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 124:23-35. 2012
  5. ncbi Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms
    David J Irwin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    Arch Neurol 69:1018-25. 2012
  6. ncbi Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
  7. ncbi Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 65:403-13. 2009
  8. ncbi Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients
    Michal J Figurski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, USA
    Alzheimers Dement 8:250-60. 2012
  9. ncbi Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
    William T Hu
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 120:385-99. 2010
  10. ncbi Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
    Christos Davatzikos
    Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neurobiol Aging 32:2322.e19-27. 2011

Collaborators

Detail Information

Publications31

  1. ncbi Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Acta Neuropathol 121:597-609. 2011
    ....
  2. ncbi Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
    ..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)...
  3. ncbi Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
    John Q Trojanowski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 6:230-8. 2010
    ..Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies...
  4. ncbi CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 124:23-35. 2012
    ....
  5. ncbi Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms
    David J Irwin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    Arch Neurol 69:1018-25. 2012
    ..To use values of cerebrospinal fluid tau and β-amyloid obtained from 2 different analytical immunoassays to differentiate Alzheimer disease (AD) from frontotemporal lobar degeneration (FTLD)...
  6. ncbi Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  7. ncbi Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 65:403-13. 2009
    ..Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects...
  8. ncbi Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients
    Michal J Figurski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, USA
    Alzheimers Dement 8:250-60. 2012
    ..The goal of this investigation was to address these problems by improving the performance of the bioanalytical method...
  9. ncbi Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
    William T Hu
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 120:385-99. 2010
    ....
  10. ncbi Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
    Christos Davatzikos
    Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neurobiol Aging 32:2322.e19-27. 2011
    ..In summary, both SPARE-AD and CSF biomarkers showed high baseline sensitivity, however, many MCI-NC had abnormal baseline SPARE-AD and CSF biomarkers. Longer follow-up will elucidate the specificity of baseline measurements...
  11. ncbi Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP, Maloney 3rd JQT or 7th LMS Floor, 36th and Spruce Streets, Philadelphia, PA, 19104 4283, USA
    Acta Neuropathol 122:401-13. 2011
    ..Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ...
  12. ncbi Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
    Sunil Patel
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Fluids Barriers CNS 9:7. 2012
    ..abstract:..
  13. ncbi Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease
    Ju Hee Kang
    Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
    Methods 56:484-93. 2012
    ....
  14. ncbi Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 8:483-9. 2012
    ..Therefore, we examined the relationship between CVRF and amyloid-β (Aβ) brain burden measured by Pittsburgh Compound B-positron emission tomography (PiB-PET) studies in the Alzheimer's Disease Neuroimaging Initiative...
  15. ncbi Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology
    Roy Hamilton
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Ann Neurol 68:535-40. 2010
    ....
  16. ncbi High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites
    Michal J Figurski
    Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Ther Drug Monit 31:717-26. 2009
    ..02%. This method was successfully applied to analyze over 11,000 samples for total analytes, and over 8000 samples for free analytes in plasma, and has been in operation for nearly 3 years without loss of performance...
  17. ncbi Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine
    Michal J Figurski
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Ther Drug Monit 30:445-55. 2008
    ..86, 4.1, and 83%, respectively. The model with 2 hours as the last time point is also recommended for the SRL group for practical reasons, with the above parameters of 0.77, 11.3, and 69%, respectively...
  18. ncbi Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup
    Magdalena Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2209-16. 2010
    ..1g of tissue for 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha)-VI, respectively, for the brain tissue method. No ion suppression or enhancement of the detection of 8-isoPGF(2alpha), 8,12-isoPF(2alpha)-VI or both internal standards was found...
  19. ncbi Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 119:669-78. 2010
    ..In summary, our targeted proteomic screen revealed novel CSF biomarkers that can improve the distinction between AD and non-AD cases by established biomarkers alone...
  20. ncbi Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters
    Michał J Figurski
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Transplant 17:68-78. 2012
    ..Additional MPA AUC measurements are recommended when trough levels do not explain the clinical picture.<br />..
  21. ncbi Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease
    Li San Wang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Alzheimers Dis 31:439-45. 2012
    ....
  22. ncbi Evaluation of performance of new, isotopically labeled internal standard ([13c2d4]RAD001) for everolimus using a novel high-performance liquid chromatography tandem mass spectrometry method
    Magdalena A Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Ther Drug Monit 33:460-3. 2011
    ....
  23. ncbi Human Alzheimer and inflammation biomarkers after anesthesia and surgery
    Junxia X Tang
    Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Anesthesiology 115:727-32. 2011
    ..The authors studied human cerebrospinal fluid (CSF) biomarkers during surgery...
  24. ncbi Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis
    David J Irwin
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Alzheimer s Disease Core Center, Institute on Aging, Philadelphia, Pennsylvania, USA
    J Neurol Neurosurg Psychiatry 84:163-9. 2013
    ..To clarify this issue, we compared a large C9P cohort with carefully matched non-expansion (C9N) cases with a known or highly-suspected underlying TAR DNA-binding protein 43 (TDP-43) proteinopathy...
  25. ncbi Design of comprehensive Alzheimer's disease centers to address unmet national needs
    John Q Trojanowski
    Institute on Aging, Philadelphia, PA, USA
    Alzheimers Dement 6:150-5. 2010
    ..The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders...
  26. ncbi Quantitation of sirolimus using liquid chromatography-tandem mass spectrometry (LC-MS-MS)
    Magdalena Korecka
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Methods Mol Biol 603:469-77. 2010
    ..5 microg/L. The quantification of drug is made from standard curve using peak-area ratio of analyte vs. internal standard. Calibration curve is constructed using non-weighted linear through zero regression...
  27. ncbi PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neurosignals 16:19-23. 2008
    ..This validation data will hopefully provide biomarker test performance needed for effective measurement of the efficacy of new treatment and prevention therapeutic agents...
  28. ncbi Therapeutic drug monitoring of mycophenolic acid
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Clin J Am Soc Nephrol 2:1062-72. 2007
  29. ncbi Quantitation of tacrolimus in whole blood using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS)
    Keri J Donaldson
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Methods Mol Biol 603:479-87. 2010
    ..75 mg/L. The concentration of drug is determined by comparing peak-area ratios for tacrolimus and internal standard to a standard curve constructed using non-weighted linear through zero regression...
  30. ncbi Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice
    Magdalena Korecka
    University of Pennsylvania, Department Pathology and Laboratory Medicine, Philadelphia, PA, USA
    Ann Transplant 14:61-72. 2009
    ..In conclusion, important features of LC-MS methodology for immunosuppressive drugs include: shortened analysis time, increased throughput, selectivity and lower cost of analysis.<br /> <br />..
  31. ncbi Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Drug Discov 6:295-303. 2007
    ....